BETA
Your AI-Trained Oncology Knowledge Connection!
Robert B. Cameron, MD, PhD, reviews data from the LAURA trial investigating osimertinib in patients with EGFR-mutated stage III unresectable NSCLC.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
FDA Approves Taletrectinib in ROS1+ NSCLC
Supporting results for the approval of taletrectinib in ROS1+ NSCLC come from the TRUST-I and TRUST-II trials.
Improving NSCLC Surgery Recovery After Climate Disaster Exposure
The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.
Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.
Navigating Management and Dosing Considerations for Amivantamab in NSCLC
Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.
An International Search for Lung Cancer Treatment Leads to Double Lung Transplant
The DREAM program led by Ankit Bharat, MD, MBBS, FACS, allowed Cornelia Tischmacher to receive a double lung transplant for her stage IV lung cancer.
Rechallenge With RET Inhibitors Shows Efficacy in Pretreated NSCLC
RET rechallenge following disease progression demonstrated greater efficacy with select combination therapies targeting bypass resistance vs single agents.